{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:57:23Z","timestamp":1761101843481},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00467-008-0846-6","type":"journal-article","created":{"date-parts":[[2008,6,5]],"date-time":"2008-06-05T14:17:54Z","timestamp":1212675474000},"page":"1461-1471","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes"],"prefix":"10.1007","volume":"23","author":[{"given":"Teruo","family":"Kitagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Odaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misao","family":"Owada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,1]]},"reference":[{"key":"846_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase\u00a0A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Knizler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733\u20133774","edition":"8"},{"key":"846_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","volume":"97","author":"R Schiffmann","year":"2000","unstructured":"Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Browski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffris NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO (2000) Infusion of a-galactosidase\u00a0A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U\u00a0S\u00a0A 97:365\u2013370","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"846_CR3","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"846_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human a-galactosidase\u00a0A replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"846_CR5","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"846_CR6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"846_CR7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1523-1755.2004.00440.x","volume":"65","author":"KC Siamopoulos","year":"2004","unstructured":"Siamopoulos KC (2004) Fabry disease: Kidney involvement and enzyme replacement therapy. Kidney Int 65:744\u2013753","journal-title":"Kidney Int"},{"key":"846_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, for the International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"846_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/18.1.33","volume":"18","author":"GD Schoenmakere","year":"2003","unstructured":"Schoenmakere GD, Chauveau D, Gr\u00fcnfeld J-P (2003) Enzyme replacement therapy in Anderson-Fabry\u2019s disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33\u201335","journal-title":"Nephrol Dial Transplant"},{"key":"846_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00041552-200403000-00012","volume":"13","author":"BM Brenner","year":"2004","unstructured":"Brenner BM, Gr\u00fcnfeld J-P (2004) Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 13:231\u2013241","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"846_CR11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N (2007) Sustained, long-term renal stabilization after 54\u00a0months of agalasidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"846_CR12","doi-asserted-by":"crossref","first-page":"s20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO (2004) Fabry disease in childhood. J Pediatr 144:s20\u2013s26","journal-title":"J Pediatr"},{"key":"846_CR13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassman G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"846_CR14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00467-004-1466-4","volume":"19","author":"ME Cho","year":"2004","unstructured":"Cho ME, Kopp JB (2004) Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 19:583\u2013593","journal-title":"Pediatr Nephrol"},{"key":"846_CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","volume":"14","author":"DG Warnock","year":"2005","unstructured":"Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14:87\u201395","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"846_CR16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"846_CR17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/clinchem\/43.8.1325","volume":"43","author":"PJ Meikle","year":"1997","unstructured":"Meikle PJ, Brooks DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, Chataway TK, Karageorgos LE, Davey RC, Boulter CD, Carlsson SR, Hopwood JJ (1997) Diagnosis of lysosomal storage disorders: evaluation of lysosome -associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 43:1325\u20131335","journal-title":"Clin Chem"},{"key":"846_CR18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/clinchem\/46.2.167","volume":"46","author":"MH Chang","year":"2000","unstructured":"Chang MH, Bindloss CA, Grabowski GA, Qi X, Winchester B, Hopwood JJ, Meikel PJ (2000) Saposins A, B, C and D in plasma of patients with lysosomal storage disorders. Clin Chem 46:167\u2013174","journal-title":"Clin Chem"},{"key":"846_CR19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","volume":"515","author":"K Mills","year":"2002","unstructured":"Mills K, Johnson A, Winchester B (2002) Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 515:171\u2013176","journal-title":"FEBS Lett"},{"key":"846_CR20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/rcm.728","volume":"16","author":"F Boscaro","year":"2002","unstructured":"Boscaro F, Pieraccini G, La Marca G, Bartolucci G, Lucerl C, Lucerl F, Moneti G (2002) Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid Commun Mass Spectrom 16:1507\u20131514","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"2","key":"846_CR21","first-page":"25","volume":"12","author":"K Suzuki","year":"2002","unstructured":"Suzuki K, Owada M, Kitagawa T (2002) Study on new screening method for Fabry\u2019s disease. J Jpn Soc Mass Screen 12(2):25","journal-title":"J Jpn Soc Mass Screen"},{"issue":"Suppl 2","key":"846_CR22","first-page":"157","volume":"26","author":"T Kitagawa","year":"2003","unstructured":"Kitagawa T, Owada M, Ishige N, Suzuki K, Ohashi T, Eto Y, Mills K, Winchester B, Keutzer J (2003) Pilot study of mass-screening for Fabry\u2019s disease (FD) by measuring globotriaosylceramide (GL-3) in whole urine samples using tandem mass spectrometry (TMS). J Inherit Metab Dis 26 [Suppl 2]:157","journal-title":"J Inherit Metab Dis"},{"key":"846_CR23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1373\/clinchem.2004.037937","volume":"50","author":"M Fuller","year":"2004","unstructured":"Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikel PJ (2004) Immunoquantification of a-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 50:1979\u20131985","journal-title":"Clin Chem"},{"key":"846_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195\u2013196","journal-title":"Clin Chim Acta"},{"key":"846_CR25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1542\/peds.2004-0583","volume":"114","author":"PJ Meikle","year":"2004","unstructured":"Meikle PJ, Ranieri E, Simonsen H, Rozakils T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ (2004) Newborn screening for lysosomal storage disorders: clinical evaluation of a two tier strategy. Pediatrics 114:909\u2013916","journal-title":"Pediatrics"},{"key":"846_CR26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.02.013","volume":"88","author":"PJ Meikle","year":"2006","unstructured":"Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA, Hopwood JJ (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88:307\u2013314","journal-title":"Mol Genet Metab"},{"key":"846_CR27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2004.035907","volume":"50","author":"Y Li","year":"2004","unstructured":"Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto M, Turecek F, Gelb MH (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785\u20131796","journal-title":"Clin Chem"},{"key":"846_CR28","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","volume":"13","author":"M Branton","year":"2002","unstructured":"Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13:S139\u2013S143","journal-title":"J Am Soc Nephrol"},{"key":"846_CR29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA III, Kopp JB (2002) Natural history of Fabry renal disease. Influence of a-galactosidase\u00a0A activity and genetic mutations on clinical course. Medicine 81:122\u2013138","journal-title":"Medicine"},{"issue":"Suppl. 8","key":"846_CR30","first-page":"317","volume":"59","author":"M Owada","year":"2001","unstructured":"Owada M, Kitagawa T (2001) Lysosomal storage diseases. Report of clinical statistics of Japan (2) (in Japanese). Nihon Rinsho 59 [Suppl 8]:317\u2013327","journal-title":"Nihon Rinsho"},{"key":"846_CR31","first-page":"157","volume":"81","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W (1973) Fabry\u2019s disease: Enzymatic diagnosis of hemizygotes and heterozygotes. a-Galactosidase\u00a0activities in plasma, serum, urine and leukocytes. J Lab Clin Med 81:157\u2013171","journal-title":"J Lab Clin Med"},{"key":"846_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","volume":"85","author":"T Kitagawa","year":"2005","unstructured":"Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J (2005) Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 85:196\u2013202","journal-title":"Mol Genet Metab"},{"key":"846_CR33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara A, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333:288\u2013293","journal-title":"N Engl J Med"},{"key":"846_CR34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ (2003) Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 64:801\u2013807","journal-title":"Kidney Int"},{"key":"846_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CNP57001","volume":"57","author":"RJ Desnick","year":"2002","unstructured":"Desnick RJ, Banikazemi M, Wasserstein M (2002) Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin Nephrol 57:1\u20138","journal-title":"Clin Nephrol"},{"key":"846_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","volume":"136","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Wasserstein MP, Banikazemi M (2001) Fabry disease (a-galactosidase\u00a0A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol 136:174\u2013192","journal-title":"Contrib Nephrol"},{"key":"846_CR37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, Gal\u00a0A, Bech M (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767\u2013772","journal-title":"Eur J Pediatr"},{"key":"846_CR38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moor DF, Sachdev V, Qurik JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal\u00a0A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R (2005) Pediatric Fabry disease. Pediatrics 115:344\u2013355","journal-title":"Pediatrics"},{"key":"846_CR39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","volume":"112","author":"JS Mayes","year":"1981","unstructured":"Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981) Differential assay for lysosomal a-galactosidases in human tissues and its application to Fabry\u2019s disease. Clin Chim Acta 112:247\u2013251","journal-title":"Clin Chim Acta"},{"key":"846_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249\u2013255","journal-title":"Kidney Int"},{"key":"846_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","volume":"92","author":"T Ohashi","year":"2007","unstructured":"Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y (2007) Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92:271\u2013273","journal-title":"Mol Genet Metab"},{"key":"846_CR42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ki.1979.128","volume":"16","author":"T Maack","year":"1979","unstructured":"Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D (1979) Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 16:251\u2013270","journal-title":"Kidney Int"},{"key":"846_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0009-8981(92)90044-Q","volume":"210","author":"DJ Vander Jagt","year":"1992","unstructured":"Vander Jagt DJ, Steinberg BR, Glew RH (1992) Comparison of urinary excretion of four lysosomal hydrolases in healthy elderly and young adults. Clin Chem Acta 210:47\u201354","journal-title":"Clin Chem Acta"},{"key":"846_CR44","first-page":"696","volume":"115","author":"RM Berty","year":"1990","unstructured":"Berty RM, Adler S, Basu A, Glew RH (1990) Effect of acid base changes on urinary hydrolases in Fabry\u2019s disease after renal transplantation. J Lab Clin Med 115:696\u2013703","journal-title":"J Lab Clin Med"},{"key":"846_CR45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF00484520","volume":"22","author":"K Paigen","year":"1984","unstructured":"Paigen K, Peterson J, Ward E (1984) A genetic component in human lysosomal enzyme excretion. Biochem Genet 22:517\u2013527","journal-title":"Biochem Genet"},{"key":"846_CR46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","volume":"338","author":"LK Hein","year":"2004","unstructured":"Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA (2004) a-L-Iduronidase premature stop codons and potential read through in mucopolysaccharidosis type 1 patients. J Mol Biol 338:453\u2013462","journal-title":"J Mol Biol"},{"key":"846_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/humu.10313","volume":"23","author":"L Karageorgos","year":"2004","unstructured":"Karageorgos L, Harmatz P, Simon J, Pollard A, Clements PR, Brooks DA, Hopwood JJ (2004) Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy. Hum Mutat 23:229\u2013233","journal-title":"Hum Mutat"},{"key":"846_CR48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-5793(97)00423-7","volume":"409","author":"DA Brooks","year":"1997","unstructured":"Brooks DA (1997) Protein processing: a role in the pathophysiology of genetic disease. FEBS Lett 409:115\u2013120","journal-title":"FEBS Lett"},{"key":"846_CR49","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1021\/bi0121149","volume":"41","author":"TM Bradford","year":"2002","unstructured":"Bradford TM, Litjens T, Parkinson EJ, Hopwood JJ, Brooks DA (2002) Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Biochemistry 41:4962\u20134971","journal-title":"Biochemistry"},{"key":"846_CR50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JM, Hollak CEM (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chem Acta 353:201\u2013203","journal-title":"Clin Chem Acta"},{"key":"846_CR51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10545-005-0039-4","volume":"28","author":"Z Lukacs","year":"2005","unstructured":"Lukacs Z, Keil A, Kohlsch\u00fctter A, Beck M, Mengel E (2005) The ratio of a-galactosidase to b-glucuronidase activities in dried blood for the identification of female Fabry disease patients. J Inherit Metab Dis 28:803\u2013805","journal-title":"J Inherit Metab Dis"},{"key":"846_CR52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s10545-007-0679-7","volume":"30","author":"Z Lukacs","year":"2007","unstructured":"Lukacs Z, Hastung R, Beck B, Keil A, Mengel E (2007) Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients. J Inherit Metab Dis 30:614","journal-title":"J Inherit Metab Dis"},{"key":"846_CR53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1399-0004.1991.tb03018.x","volume":"39","author":"Y Nagao","year":"1991","unstructured":"Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, Mori Y, Sakuraba H, Suzuki Y (1991) Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase\u00a0A. Clin Genet 39:233\u2013237","journal-title":"Clin Genet"},{"key":"846_CR54","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407\u20131411","journal-title":"Circulation"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-008-0846-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0846-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:14:01Z","timestamp":1610817241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-008-0846-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1007\/s00467-008-0846-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"21 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}